نتایج جستجو برای: flt3 tyrosine kinase

تعداد نتایج: 262799  

2014
Ghaleb Elyamany Mohammad Awad Kamal Fadalla Mohamed Albalawi Mohammad Al Shahrani Abdulaziz Al Abdulaaly

The Fms-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase that plays a key role in cell survival, proliferation, and differentiation of hematopoietic stem cells. Mutations of FLT3 were first described in 1997 and account for the most frequent molecular mutations in acute myeloid leukemia (AML). AML patients with FLT3 internal tandem duplication (ITD) mutations have poor cure rates the...

Journal: :BioMedInformatics 2022

Acute myeloid leukemia (AML), a hematologic malignancy that results in bone marrow failure, is the most common acute adults. The presence of FMS-related tyrosine kinase 3 (FLT3) mutations associated with poor prognosis, making evaluation FLT3-inhibitors an imperative goal clinical trials. Midostaurin was first FLT3-inhibitor approved by FDA and EMA for treatment FLT3-mutated AML, it showed sign...

2016
Amanda M. Smith Matthew D. Dun Erwin M. Lee Celeste Harrison Richard Kahl Hayley Flanagan Nikita Panicker Baratali Mashkani Anthony S. Don Jonathan Morris Hamish Toop Richard B. Lock Jason A. Powell Daniel Thomas Mark A. Guthridge Andrew Moore Leonie K. Ashman Kathryn A. Skelding Anoop Enjeti Nicole M. Verrills

Constitutive activation of the receptor tyrosine kinase Fms-like tyrosine kinase 3 (FLT3), via co-expression of its ligand or by genetic mutation, is common in acute myeloid leukemia (AML). In this study we show that FLT3 activation inhibits the activity of the tumor suppressor, protein phosphatase 2A (PP2A). Using BaF3 cells transduced with wildtype or mutant FLT3, we show that FLT3-induced PP...

2012
Julhash U. Kazi Lars Rönnstrand

Fms-like tyrosine kinase 3 (Flt3) is an important growth factor receptor in hematopoiesis. Gain-of-function mutations of the receptor contribute to the transformation of acute myeloid leukemia (AML). Src-like adaptor protein (SLAP) is an interaction partner of the E3 ubiquitin ligase Cbl that can regulate receptor tyrosine kinases-mediated signal transduction. In this study, we analyzed the rol...

Journal: :Cancer research 2009
Nikolas von Bubnoff Richard A Engh Espen Aberg Jana Sänger Christian Peschel Justus Duyster

FMS-like tyrosine kinase 3 (FLT3) inhibitors have shown activity in the treatment of acute myelogenous leukemia (AML). Secondary mutations in target kinases can cause clinical resistance to therapeutic kinase inhibition. We have previously shown that sensitivity toward tyrosine kinase inhibitors varies between different activating FLT3 mutations. We therefore intended to determine whether diffe...

Journal: :Blood 2004
B Douglas Smith Mark Levis Miloslav Beran Francis Giles Hagop Kantarjian Karin Berg Kathleen M Murphy Tianna Dauses Jeffrey Allebach Donald Small

Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30% of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment. Targeting the mutation by inhibiting the tyrosine kinase activity of FLT3 is cytotoxic to cell lines and primary AML cells harboring FLT3 mutations. Successful FLT3 in...

2004
B. Douglas Smith Mark Levis Miloslav Beran Francis Giles Hagop Kantarjian Karin Berg Kathleen M. Murphy Tianna Dauses Jeffrey Allebach

Activating mutations of FMS-like tyrosine kinase 3 (FLT3) are present in approximately 30% of patients with de novo acute myeloid leukemia (AML) and are associated with lower cure rates from standard chemotherapy-based treatment. Targeting the mutation by inhibiting the tyrosine kinase activity of FLT3 is cytotoxic to cell lines and primary AML cells harboring FLT3 mutations. Successful FLT3 in...

بخشایش, معصومه, ذاکر, فرهاد, محمدی, محمد حسین, کاظمی, احمد ,

    Background and Aim: Molecular basis of Acute Myeloid Leukemia (AML) involves mutations in regulatory genes of cellular proliferation and differentiation.Mutation in tyrosine kinase receptor gene of FLT3 occurs in high frequency in AML, resulting in proliferation and abnormal survival of leukemia cells. Mutations in Internal Tandem Duplication (ITD) and D835 of FLT3 gene are associated with ...

2015
Julie A. Zorn Qi Wang Eric Fujimura Tiago Barros John Kuriyan

More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clinical trials appears promising for the treatment of AML. Here, we report the co-crystal structure of the kinase domain of FLT3 in complex with quizartinib...

Journal: :Blood 2005
Chunaram Choudhary Joachim Schwäble Christian Brandts Lara Tickenbrock Bülent Sargin Thomas Kindler Thomas Fischer Wolfgang E Berdel Carsten Müller-Tidow Hubert Serve

Activating mutations of Flt3 are found in approximately one third of patients with acute myeloid leukemia (AML) and are an attractive drug target. Two classes of Flt3 mutations occur: internal tandem duplications (ITDs) in the juxtamembrane and point mutations in the tyrosine kinase domain (TKD). We and others have shown that Flt3-ITD induced aberrant signaling including strong activation of si...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید